PubRank

L Eijsman

Author PubWeight™ 44.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990 3.22
2 Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997 2.41
3 Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997 1.67
4 Transvascular transport of 67Ga in the lungs after cardiopulmonary bypass surgery. Chest 1993 1.64
5 Perivenous application of fibrin glue reduces early injury to the human saphenous vein graft wall in an ex vivo model. Eur J Cardiothorac Surg 2002 1.48
6 Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992 1.45
7 Effects of calcium, inorganic phosphate, and pH on isometric force in single skinned cardiomyocytes from donor and failing human hearts. Circulation 2001 1.21
8 Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990 1.19
9 Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004 1.17
10 Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995 1.15
11 Force production in mechanically isolated cardiac myocytes from human ventricular muscle tissue. Cardiovasc Res 1998 1.03
12 Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995 0.89
13 Perivenous support reduces early changes in human vein grafts: studies in whole blood perfused human vein segments. J Thorac Cardiovasc Surg 2001 0.89
14 Isometric tension development and its calcium sensitivity in skinned myocyte-sized preparations from different regions of the human heart. Cardiovasc Res 1999 0.88
15 N(epsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 2006 0.87
16 Reduced renal failure following thoracoabdominal aortic aneurysm repair by selective perfusion. Eur J Cardiothorac Surg 1998 0.86
17 Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991 0.86
18 Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur J Cardiothorac Surg 1994 0.85
19 Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. J Cardiovasc Pharmacol 1997 0.84
20 The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 2004 0.83
21 Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003 0.82
22 Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 2000 0.81
23 Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis. Transfus Med 2007 0.80
24 Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg 1997 0.80
25 Aprotinin administration in the pericardial cavity does not prevent platelet activation. J Thorac Cardiovasc Surg 2000 0.80
26 Interstitial fluid volume during cardiac surgery measured by means of a non-invasive conductivity technique. Acta Anaesthesiol Scand 1995 0.80
27 Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998 0.79
28 Influence of heparin, protamine and polybrene on the time integral of thrombin generation (endogenous thrombin potential). Haemostasis 1996 0.79
29 Biocompatibility of three different membrane oxygenators: effects on complement, neutrophil and monocyte activation. Perfusion 1997 0.78
30 Cardiopulmonary bypass with modified fluid gelatin and heparin-coated circuits. Br J Anaesth 1996 0.78
31 Activated complement is more extensively present in diseased aortic valves than naturally occurring complement inhibitors: a sign of ongoing inflammation. Eur J Clin Invest 2009 0.78
32 Topical vascular endothelial growth factor in rabbit tracheal surgery: comparative effect on healing using various reconstruction materials and intraluminal stents. Eur J Cardiothorac Surg 2003 0.77
33 Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 1994 0.77
34 Hemostatic function of aspirin-treated platelets vulnerable to cardiopulmonary bypass. Altered shear-induced pathway. J Thorac Cardiovasc Surg 1995 0.77
35 Induction and detection of disturbed homeostasis in cardiopulmonary bypass. Perfusion 2004 0.77
36 The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993 0.77
37 The routine use of fresh frozen plasma in operations with cardiopulmonary bypass is not justified. J Thorac Cardiovasc Surg 1996 0.76
38 Effects of dobutamine and enoximone on transmitral and pulmonary venous flow characteristics in patients with left ventricular dysfunction after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1996 0.76
39 Circulating endothelin in cardiac operations: influence of blood pressure and endotoxin. Ann Thorac Surg 1996 0.76
40 Specific complement inhibition with heparin-coated extracorporeal circuits. Ann Thorac Surg 1996 0.76
41 Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. J Thorac Cardiovasc Surg 1995 0.76
42 Let's understand nature better: de- and regeneration of autologous and artificial small caliber vascular grafts. Artif Organs 1998 0.76
43 Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg 1996 0.75
44 Brain swelling after coronary surgery. Lancet 1993 0.75
45 Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. Ann Thorac Surg 1998 0.75
46 Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass. Ann Thorac Surg 1995 0.75
47 Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989 0.75
48 Increased infiltration of Chlamydophila pneumoniae in the vessel wall of human veins after perfusion. Eur J Clin Invest 2008 0.75
49 Endotoxaemia and postoperative hypermetabolism in coronary artery bypass surgery: the role of ketanserin. Br J Anaesth 1996 0.75
50 Platelet preservation by aprotinin during cardiopulmonary bypass. Lancet 1988 0.75
51 Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response. Eur J Cardiothorac Surg 2004 0.75
52 Biphasic release of secretory phospholipase A2 during and after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998 0.75
53 Hemodynamic side effects of prostaglandin E1 in patients before and during cardiopulmonary bypass. Thorac Cardiovasc Surg 1981 0.75
54 Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1995 0.75
55 Surgical sealant in the prevention of early vein graft injury in an ex vivo model. Cardiovasc Pathol 2003 0.75
56 [Supplementary extracorporeal oxygenation (SECO)]. Ned Tijdschr Geneeskd 1974 0.75
57 Comparison of three commercially available hollow fiber oxygenators: gas transfer performance and biocompatibility. ASAIO J 2001 0.75